Top of the morning to you, and a fine one it is. Despite the gray skies hovering over the Pharmalot campus, our outlook remains sunny today. And why not? As the Morning Mayor taught us, every new day should be unwrapped like a precious gift. So while you tug on the ribbon, you can also peruse some of the items we have gathered to help you on your journey today. As always, we wish you success and, of course, do keep in touch. We appreciate tips, insights, and secret dossiers. …

The Trump administration will not join an international cooperative effort to develop, manufacture, and distribute a Covid-19 vaccine, in part, because the World Health Organization is involved, a decision that could shape the course of the pandemic and the country’s role in health diplomacy, The Washington Post reports. More than 170 countries are in talks to participate in the so-called Covax facility, which aims to speed vaccine development, secure doses for all countries, and distribute them to the most high-risk segment of each population.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy